Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and ...

President-elect Donald Trump reportedly tapped anti-vaccine activist Robert F Kennedy Jr to lead the Department of Health and ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such ...

A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Jacobs acknowledged that Novavax does not have the market leverage and scale of French drugmaker Sanofi, with which it signed ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Recent health news highlights include Recordati's nonchalance towards potential U.S. tariffs, Canada's approval of Moderna's ...

[emphasis in original] Yee cited by name Moderna (NASDAQ: MRNA) as an example of a vaccine developer hurt by declining ...